ALK Abello (ALK-B.CO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ALK-B.CO · Stock Price

DKK 258.40+94.50 (+57.66%)

Market Cap: $8.9B

Historical price data

Market Cap: $8.9BFounded: 1923HQ: Hørsholm, Denmark

Sector Ranking#3 in Immunotherapy / Immuno-Oncology #15 in Diagnostics & Precision Medicine

Overview

ALK Abelló's mission is to pioneer allergy immunotherapy solutions that improve and protect the lives of people with allergies globally. The company has achieved a dominant position in the AIT market through its proprietary sublingual tablet technology and a robust commercial portfolio. Its 'Allergy+' strategy for 2024-2028 focuses on expanding its patient reach, advancing a novel pipeline in food allergy and anaphylaxis, and leveraging digital innovation, as evidenced by strong 2025 financials with 15% revenue growth and a 26% EBIT margin.

Respiratory AllergyFood AllergyAnaphylaxis

Technology Platform

ALK's platform integrates proprietary allergen standardization, pioneering sublingual tablet (SLIT) delivery, translational research from a vast clinical biobank, and modern AI-driven drug discovery tools to accelerate the development of allergy immunotherapies.

Funding History

1

Total raised:$500M

IPO$500MNordeaJun 15, 2007

Opportunities

The global allergy market is large and underpenetrated, with significant growth potential from rising prevalence, the shift towards disease-modifying AIT, and expansion into high-need areas like food allergy.

ALK's needle-free anaphylaxis treatment (EURneffy®) disrupts a established market and addresses key patient unmet needs.

Risk Factors

Key risks include clinical and regulatory setbacks in the high-stakes food allergy pipeline, intense competition in the anaphylaxis device market, and the execution risk associated with the ambitious 5-million-patient target.

The recent departure of the Head of R&D also introduces transition risk.

Competitive Landscape

ALK is the global leader in allergy immunotherapy, competing with firms like Stallergenes Greer in respiratory AIT. In anaphylaxis, it competes with auto-injector giants (EpiPen) with its disruptive needle-free spray. In food allergy, it faces biotechs developing biologic therapies, leveraging its unique AIT expertise.